NEW YORK (GenomeWeb News) – Bio-Rad Laboratories today reported that second-quarter revenue grew 9 percent as net income jumped 75 percent.
 
The results helped drive up shares in Bio-Rad by more than 5 percent, or $3.30, to $68.43 in mid-afternoon trading.
 
Receipts for the three months ended June 30 increased to $317.7 million from $291.3 million year over year. The company included a one-time licensing settlement of $11.7 million from bioMérieux.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.